All articles by Catrin Jackson – Page 4
-
Industry newsFDA's Emerging Technology Programme
The FDA’s Emerging Technology Programme intends to assist industry in gaining regulatory approval for innovative technology drug applications.
-
Industry newsFDA approves its first nonprescription birth control pill
FDA approves first over-the-counter (OTC) contraceptive pill for use in the US − it is expected to become the most effective OTC birth control.
-
Industry newsGood safety profile of COVID-19 vaccines declared by ICMRA
COVID-19 vaccines show a very good safety profile in all age groups, including people with underlying medical conditions and pregnancy.
-
Industry newsMHRA Corporate Plan supports access for patients to innovation
The MHRA’s Corporate Plan for 2023-26 seeks to set out how it will enable access to innovative medical products while ensuring patient safety.
-
Industry newsWellcome grants £5.7 million to combat MRSA
The Wellcome Trust’s Discovery Award has granted £5.7 million to a University of Sheffield team for research into antibiotic resistance.
-
Industry newsAI-generated drug first to reach Phase II trials
Insilico Biotech’s INS018_055 – a drug generated by AI – is a treatment for a rare lung disease and the first AI drug to enter a Phase II trial.
-
Industry newsStakeholder feedback sought on EMA draft clinical guidelines
The EMA has published draft guidance − ICH E6 (R3) − on good clinical practice for clinical trials, which is open for public consultation.
-
Industry newsTwo paediatric type 2 diabetes oral drugs receive FDA approval
FDA approves Jardiance and Synjardy as treatments to improve the control of blood sugar in children aged 10 years and older, with type 2 diabetes.
-
Industry newsNHS to receive £21 million fund for AI diagnostics
NHS Trusts will be able to apply to a dedicated AI diagnostics fund which totals £21 million, the Secretary of State for Health and Social Care announced.
-
Industry newsUK and Ireland VetMed product label guidance
Ireland’s HPRA and the UK’s VMD have produced interim guidance clarifying the joint labels for veterinary medicines authorised in the two countries.
-
Industry newsUmbrella EU-US VetMed MRA comes one step closer
EU and US make progress towards a mutual recognition agreement for manufacturing inspections of veterinary products.
-
Industry newsNICE recommends its first-ever oral migraine treatment
Rimegapant – has been approved for use in the NHS giving a treatment option for people who have failed with different drug options.
-
Industry newsMHRA plans medical device technologies streamlined pathway
UK agency aims to make route-to-market much more straightforward for manufacturers with Innovative Devices Access Pathway.
-
Industry newsMHRA seals deal for fast international recognition routes
UK agency adopts recognition routes from seven national authorities; new signals start of new international framework for medicines.
-
Industry newsGene therapy gives hope to patients with ‘butterfly skin’
FDA approves first gene therapy to treat dystrophic epidermolysis
bullosa patients – a condition sometimes called ‘butterfly skin’. -
Industry newsNovel gene editing method “roughly threefold” better
Researchers from the University of California Santa Barbara (UCSB) have found two ways to boost the capabilities of CRISPR/Cas9.
-
Industry newsFDA licence for first drug to treat agitation in Alzheimer’s
Rexulti has become the first FDA-approved treatment for agitation associated with dementia due to Alzheimer’s disease.
-
Industry newsFirst anaemia drug for cats given ‘expanded conditional approval’
Varenzin-CA1 is the first drug approved for cats with nonregenerative
anaemia, under the FDA’s expanded conditional approval pathway. -
Industry newsFDA approves world’s first RSV vaccine for use in over 60s
A first vaccine, developed by GSK, for respiratory syncytial virus has been approved by the FDA for use in adults aged 60 years and older.
-
Industry newsMHRA reappoints two non-exec directors
Two Non-Executive Directors have been reappointed to the MHRA Board effective from September 1, 2023, according to the Department of Health and Social Care.
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page